BiotechTube

Eribulin + Cyclophosphamide

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malignant Solid Tumour

Conditions

Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, Neuropathy

Trial Timeline

Mar 27, 2012 → Dec 31, 2019

NCT ID
NCT01554371

About Eribulin + Cyclophosphamide

Eribulin + Cyclophosphamide is a phase 1/2 stage product being developed by Eisai for Malignant Solid Tumour. The current trial status is completed. This product is registered under clinical trial identifier NCT01554371. Target conditions include Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, Neuropathy.

What happened to similar drugs?

5 of 20 similar drugs in Malignant Solid Tumour were approved

Approved (5) Terminated (2) Active (13)
✅Deep Neuromuscular Blockade (NMB) + Moderate Neuromuscular Blockade (NMB) + Sugammadex + NeostigmineMerckApproved
✅Rocuronium + Sugammadex + Neostigmine + GlycopyrrolateMerckApproved
✅ZelborafRocheApproved
✅Atezolizumab Injection [Tecentriq]RocheApproved
✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01554371Phase 1/2Completed

Competing Products

20 competing products in Malignant Solid Tumour

See all competitors
ProductCompanyStageHype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabCSPC Pharmaceutical Group LimitedPhase 1/2
39
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Tadalafil + GemcitabineEli LillyPhase 1
29
Patritumab DeruxtecanDaiichi SankyoPhase 1/2
39
Tivantinib + FOLFOXDaiichi SankyoPhase 1/2
32
DS-1123Daiichi SankyoPhase 1
29
DS-8201aDaiichi SankyoPhase 1
29
DS-5573aDaiichi SankyoPhase 1
21
DS-6051bDaiichi SankyoPhase 1
29
U3-1565Daiichi SankyoPhase 1
29
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue MedicationsDaiichi SankyoPhase 1/2
39
DS-3201b + DS-3201bDaiichi SankyoPhase 1
33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kgDaiichi SankyoPhase 1
29
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
39
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
39
CP-461Astellas PharmaPhase 2
27
enfortumab vedotinAstellas PharmaPhase 1
29
LNF1901 Monoclonal Antibody InjectionSun PharmaceuticalPhase 1
36
Perampanel + Standard of CareEisaiPhase 1/2
32
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
40